AB 420: The California Cannabis Research Program.
- Session Year: 2019-2020
- House: Assembly
- Latest Version Date: 2019-10-12
|
Date
|
Status
|
|---|---|
| Oct 12, 2019 | Chaptered by Secretary of State - Chapter 802, Statutes of 2019. |
| Oct 12, 2019 | Approved by the Governor. |
| Sep 12, 2019 | Enrolled and presented to the Governor at 3:30 p.m. |
| Sep 9, 2019 | Senate amendments concurred in. To Engrossing and Enrolling. (Ayes 79. Noes 0.). |
| Sep 6, 2019 | In Assembly. Concurrence in Senate amendments pending. May be considered on or after September 8 pursuant to Assembly Rule 77. |
| Sep 5, 2019 | Read third time. Urgency clause adopted. Passed. Ordered to the Assembly. |
| Aug 30, 2019 | From committee: Do pass. (Ayes 7. Noes 0.) (August 30). |
| Aug 12, 2019 | In committee: Referred to APPR. suspense file. |
| Jul 8, 2019 | From committee chair, with author's amendments: Amend, and re-refer to committee. Read second time, amended, and re-referred to Com. on APPR. |
| Jun 18, 2019 | In committee: Set, first hearing. Hearing canceled at the request of author. |
| Jun 11, 2019 | Read second time and amended. Re-referred to Com. on APPR. |
| Jun 10, 2019 | From committee: Amend, and do pass as amended and re-refer to Com. on APPR. (Ayes 9. Noes 0.) (June 3). |
| May 28, 2019 | From committee chair, with author's amendments: Amend, and re-refer to committee. Read second time, amended, and re-referred to Com. on B., P. & E.D. |
| Apr 24, 2019 | Referred to Com. on B., P. & E.D. |
| Apr 11, 2019 | In Senate. Read first time. To Com. on RLS. for assignment. |
| Apr 11, 2019 | Read third time. Urgency clause adopted. Passed. Ordered to the Senate. |
| Apr 4, 2019 | Read second time. Ordered to Consent Calendar. |
| Apr 3, 2019 | From committee: Do pass. To Consent Calendar. (Ayes 17. Noes 0.) (April 3). |
| Mar 26, 2019 | From committee: Do pass and re-refer to Com. on APPR. (Ayes 20. Noes 0.) (March 26). Re-referred to Com. on APPR. |
| Feb 15, 2019 | Referred to Com. on B. & P. |
| Feb 8, 2019 | From printer. May be heard in committee March 10. |
| Feb 7, 2019 | Read first time. To print. |
|
Date
|
Description
|
Location
|
Votes
|
|
|---|---|---|---|---|
| Sep 9, 2019 | AB 420 Lackey Concurrence in Senate Amendments | Assembly Floor |
Passed |
|
| Sep 5, 2019 | Assembly 3rd Reading AB420 Lackey et al. By Hertzberg Urgency Clause | Senate Floor |
Passed |
|
| Aug 30, 2019 | Do pass | Senate Standing Committee on Appropriations |
Passed |
|
| Aug 12, 2019 | Placed on suspense file | Senate Standing Committee on Appropriations |
Passed |
|
| Jun 3, 2019 | Do pass as amended, but first amend, and re-refer to the Committee on [Appropriations] | Senate Standing Committee on Business, Professions and Economic Development |
Passed |
|
| Apr 11, 2019 | AB 420 Lackey Consent Calendar Second Day Regular Session | Assembly Floor |
Passed |
|
| Apr 3, 2019 | Do pass. To Consent Calendar. | Assembly Standing Committee on Appropriations |
Passed |
|
| Mar 26, 2019 | Do pass and be re-referred to the Committee on [Appropriations] | Assembly Standing Committee on Business and Professions |
Passed |
This list shows positions taken on this bill by organizations on the date displayed, which is linked to the original source.
Positions by individuals are not included.
CONCURRENCE IN SENATE AMENDMENTS
CSA1 Bill Id:AB 420
Author:(Lackey and Cooley)
As Amended Ver:July 8, 2019
2/3 vote. Urgency
SUMMARY:
This bill authorizes the California Cannabis Research Program (CCRP) to cultivate its own cannabis for the research project, and expand what studies may examine, including mold, bacteria, and mycotoxins.
The Senate Amendments:
Authorizes the President of the University of California, or the president's designee to appoint a multidisciplinary Scientific Advisory Council.
Ensures that all cannabis used in the studies is of the appropriate medicinal quality. Cannabis used by the program may be obtained from the National Institute on Drug Abuse or any other entity authorized by the appropriate federal agencies, the Attorney General pursuant to Section 11478, or may be cultivated by the program pursuant to applicable federal and state laws and regulations.
COMMENTS:
The Center for Medicinal Cannabis Research (CMCR) was created through SB 847 (Vasconcellos, Chapter 750, Statutes of 1999), also known as the Marijuana Research Act of 1999. SB 847 authorized the UC Regents to create a program called the CCRP, which would conduct scientific studies to assess the safety and efficacy of cannabis and, if found valuable, to develop medical guidelines for its appropriate use. CMCR is housed at UC San Diego. CMCR's studies have thus far examined the efficacy of cannabis as a painkiller and its value for the treatment of spasticity in multiple sclerosis. Current studies are examining the effects of cannabis on pain, as well as public safety issues surrounding the use of cannabis and Cannabidiol (CBD).
There are numerous challenges and barriers to conducting research on cannabis and cannabinoids, including regulatory barriers and difficulty in obtaining the quantity, quality, and type of cannabis necessary to address relevant research questions.
Researchers may currently only obtain cannabis through the National Institute on Drug Abuse's Drug Supply Program. The University of Mississippi is the only entity authorized by the Drug Enforcement Agency (DEA) to cultivate cannabis for research purposes in the United States, and has been since 1968. This has led to supply shortages and created a lack of diversity in cannabis strains and products available for research. This bill authorizes CMCR to cultivate cannabis for its own research purposes. They would still need to seek the approval of the DEA to do so within a federally legal framework, however. CMCR would not qualify for a license under the state's commercial cannabis framework.
According to the Author:
According to the Author, "The fact is we still don't know everything there is to know about cannabis use. The problem, however, is not what we don't know about it, the problem is that we don't have enough of the plant to study. CMCR is a premier organization that the Legislature created and trusts; this bill would show how much we trust them and legitimize the research even more."
Arguments in Support:
According to Eaze, "[This bill] seeks to address potential confusion in cannabis studies and allow for a more comprehensive research option…. By adding synthetic cannabinoids to the readily available substances to study, the scope of research is broadened to include a range of cannabinoids and other cannabis-related compounds that will allow for a more comprehensive study and understanding of the substance. By authorizing CMCR to cultivate their own crop of cannabis (or in collaboration with other Federally-approved entities), researchers will be able to better research the types of cannabis products that may be most beneficial for various conditions, and may be most informative about the potential public health impacts of cannabis use."
Arguments in Opposition:
None on file
FISCAL COMMENTS:
According to the Senate Appropriations Committee, negligible impact to the Department of Justice, University of California, Bureau of Cannabis Control.
VOTES:
ASM BUSINESS AND PROFESSIONS: 20-0-0
YES: Low, Brough, Bloom, Chen, Chiu, Cunningham, Dahle, Eggman, Fong, Gipson, Gloria, Grayson, Holden, Irwin, McCarty, Medina, Mullin, Obernolte, Quirk-Silva, Ting
ASM APPROPRIATIONS: 17-0-1
YES: Gonzalez, Bigelow, Bloom, Bonta, Brough, Calderon, Carrillo, Chau, Diep, Eggman, Fong, Gabriel, Friedman, Obernolte, Petrie-Norris, Quirk, Robert Rivas
ABS, ABST OR NV: Maienschein
ASSEMBLY FLOOR: 72-0-8
YES: Aguiar-Curry, Bauer-Kahan, Bigelow, Bloom, Boerner Horvath, Bonta, Brough, Burke, Calderon, Carrillo, Cervantes, Chau, Chen, Choi, Chu, Cooper, Cunningham, Dahle, Daly, Diep, Eggman, Flora, Fong, Friedman, Gabriel, Gallagher, Cristina Garcia, Gipson, Gloria, Gonzalez, Gray, Grayson, Holden, Irwin, Jones-Sawyer, Kalra, Kamlager-Dove, Kiley, Lackey, Limón, Maienschein, Mathis, Mayes, McCarty, Medina, Melendez, Mullin, Muratsuchi, Nazarian, O'Donnell, Obernolte, Patterson, Petrie-Norris, Quirk, Quirk-Silva, Ramos, Reyes, Luz Rivas, Robert Rivas, Rodriguez, Blanca Rubio, Salas, Santiago, Smith, Mark Stone, Ting, Voepel, Waldron, Weber, Wicks, Wood, Rendon
ABS, ABST OR NV: Arambula, Berman, Chiu, Cooley, Frazier, Eduardo Garcia, Levine, Low
SENATE FLOOR: 39-0-1
YES: Allen, Archuleta, Atkins, Bates, Beall, Borgeas, Bradford, Caballero, Chang, Dahle, Dodd, Durazo, Galgiani, Glazer, Lena Gonzalez, Grove, Hertzberg, Hill, Hueso, Hurtado, Jackson, Jones, Leyva, McGuire, Mitchell, Monning, Moorlach, Nielsen, Pan, Portantino, Roth, Rubio, Skinner, Stern, Stone, Umberg, Wieckowski, Wiener, Wilk
ABS, ABST OR NV: Morrell
UPDATED:
VERSION: July 8, 2019
CONSULTANT: Danielle Sires / B. & P. / (916) 319-3301 FN: 0002060
Office of Senate Floor Analyses (916) 651-1520 Fax: (916) 327-4478 | AB 420 |
THIRD READING
Bill No: AB 420
Author: Lackey (R) and Cooley (D), et al.
Amended: 7/8/19 in Senate
SENATE BUS., PROF. & ECON. DEV. COMMITTEE: 9-0, 6/3/19
AYES: Glazer, Chang, Archuleta, Dodd, Galgiani, Hill, Leyva, Pan, Wilk
SENATE APPROPRIATIONS COMMITTEE: 7-0, 8/30/19
AYES: Portantino, Bates, Bradford, Durazo, Hill, Jones, Wieckowski
ASSEMBLY FLOOR: 72-0, 4/11/19 (Consent) - See last page for vote
SUBJECT: The California Cannabis Research Program
DIGEST:
This bill authorizes the California Cannabis Research Program (CCRP) to cultivate its own cannabis for the research project, and expand what studies may examine, including mold, bacteria, and mycotoxins.
Existing law:
- Requires the Bureau of Cannabis Control (BCC) to contract with the Center for Medicinal Cannabis Research (CMCR) to develop a study that identifies cannabis’ impact on motor skills. (Business and Professions Code (BPC) § 26190.5)
- States the intent of the Legislature for the state to commission objective scientific research by the University of California (UC) regarding the efficacy and safety of medical cannabis. Requires the UC, by appropriate resolution, to create CCRP. (Health and Safety Code (HSC) § 11362.9(a)(1))
- Requires CCRP to develop and conduct studies to ascertain the general medical safety and efficacy of cannabis and, if valuable, develop medical guidelines for cannabis’s appropriate administration and use. Authorizes these studies to ascertain cannabis’s effects on motor skills. (HSC § 11362.9(a)(2))
- Authorizes CCRP to seek outside funding and prohibits CCRP from accepting funds that are not intended for use other than to solely study the efficacy and safety of cannabis as part of medical treatment. (HSC § 11362.9(n))
- Requires the State Controller to disburse $10 million to a public university or universities in California annually from fiscal year 2018-10 to 2028-29 to research and evaluate the implementation and effect of the Control, Regulate and Tax Adult Use of Marijuana Act. (Revenue and Taxation Code (RTC) § 34019(b))
This bill:
- Expands the scope of CCRP’s studies to include the examination of the health and safety effects of cannabis, cannabinoids and other related constituents, and other behavioral health outcomes.
- Authorizes CCRP to cultivate the cannabis used in studies, as specified.
- Authorizes CCRP studies to focus on examining testing methods for detecting harmful contaminants in cannabis.
- Lengthens the frequency at which CCRP must issue a report detailing the progress of the studies to the Legislature to every 24 months.
- Authorizes a designee of the President of the UC to appoint a Scientific Advisory Council.
- Requires that money appropriated to CCRP through the program only be used in compliance with the provisions of AUMA, and does not limit or preclude cannabis-related research activities at any campus of the UC.
Background
The Center for Medicinal Cannabis Research. CMCR was created through SB 847 (Vasconcellos, Chapter 750, Statutes of 1999), also known as the Marijuana Research Act of 1999. SB 847 authorized the UC Regents to create a program called the CCRP, which would conduct scientific studies to assess the safety and efficacy of cannabis and, if found valuable, to develop medical guidelines for its appropriate use. CMCR is housed at UC San Diego. CMCR’s studies have thus far examined the efficacy of cannabis as a painkiller and its value for the treatment of spasticity in multiple sclerosis. Current studies are examining the effects of cannabis on pain, as well as public safety issues surrounding the use of cannabis and CBD.
Cannabis access at research institutions. There are numerous challenges and barriers to conducting research on cannabis and cannabinoids, including regulatory barriers and difficulty in obtaining the quantity, quality, and type of cannabis necessary to address relevant research questions.
Researchers may currently only obtain cannabis through the National Institute on Drug Abuse’s Drug Supply Program. The University of Mississippi is the only entity authorized by the Drug Enforcement Agency (DEA) to cultivate cannabis for research purposes in the US, and has been since 1968. This has led to supply shortages and created a lack of diversity in cannabis strains and products available for research. This bill authorizes CMCR to cultivate cannabis for its own research purposes. They would still need to seek the approval of the DEA to do so within a federally legal framework, however. CMCR would not qualify for a license under the state’s commercial cannabis framework.
FISCAL EFFECT: Appropriation: No Fiscal Com.: Yes Local: No
According to the Senate Appropriations Committee, this bill will have a negligible impact to the Department of Justice, UC, BCC.
Cal NORML
California Cannabis Coalition
California Cannabis Industry Association
Eaze
NorCal Cannabis
OPPOSITION: (Verified 8/30/19)
None received
ARGUMENTS IN SUPPORT: According to Eaze, “AB 420 seeks to address potential confusion in cannabis studies and allow for a more comprehensive research option…. By adding synthetic cannabinoids to the readily available substances to study, the scope of research is broadened to include a range of cannabinoids and other cannabis-related compounds that will allow for a more comprehensive study and understanding of the substance. By authorizing CMCR to cultivate their own crop of cannabis (or in collaboration with other Federally-approved entities), researchers will be able to better research the types of cannabis products that may be most beneficial for various conditions, and may be most informative about the potential public health impacts of cannabis use.”
ASSEMBLY FLOOR: 72-0, 4/11/19
AYES: Aguiar-Curry, Bauer-Kahan, Bigelow, Bloom, Boerner Horvath, Bonta, Brough, Burke, Calderon, Carrillo, Cervantes, Chau, Chen, Choi, Chu, Cooper, Cunningham, Dahle, Daly, Diep, Eggman, Flora, Fong, Friedman, Gabriel, Gallagher, Cristina Garcia, Gipson, Gloria, Gonzalez, Gray, Grayson, Holden, Irwin, Jones-Sawyer, Kalra, Kamlager-Dove, Kiley, Lackey, Limón, Maienschein, Mathis, Mayes, McCarty, Medina, Melendez, Mullin, Muratsuchi, Nazarian, Obernolte, O'Donnell, Patterson, Petrie-Norris, Quirk, Quirk-Silva, Ramos, Reyes, Luz Rivas, Robert Rivas, Rodriguez, Blanca Rubio, Salas, Santiago, Smith, Mark Stone, Ting, Voepel, Waldron, Weber, Wicks, Wood, Rendon
NO VOTE RECORDED: Arambula, Berman, Chiu, Cooley, Frazier, Eduardo Garcia, Levine, Low
Prepared by: Samantha Tucci / B., P. & E.D. / 916-612-651-4104
9/1/19 10:50:18
**** END ****
SENATE COMMITTEE ON
Senator Anthony Portantino, Chair
2019 - 2020 Regular Session
AB 420 (Lackey) - The California Cannabis Research Program
Version: | Policy Vote: |
Urgency: | Mandate: |
Hearing Date: | Consultant: |
Bill Summary:
AB 420 would authorize the California Cannabis Research Program to cultivate its own cannabis for the research project, and expand what studies may examine, including mold, bacteria, and mycotoxins.
Fiscal Impact:
Negligible impact to the Department of Justice (DOJ), University of California (UC), Bureau of Cannabis Control (Bureau).
Background:
SB 847 (Vasconcellos, Chapter 750, Statutes of 1999) enacted the Marijuana Research Act of 1999, which authorized the University of California Regents to implement a California Marijuana Research Program, to study the medical safety and marijuana. The Program can solicit, apply for, and accept funds from foundations, private individuals, and all other funding sources to expand the scope or timeframe of the cannabis studies. The Center for Medicinal Cannabis Research is housed at the University of California, San Diego. Current studies include: the efficacy of cannabis as a painkiller, specifically the treatment of spasticity in multiple sclerosis, and public safety issues. Current law requires the program to ensure that all cannabis used in their studies is of appropriate quality and is obtained from the National Institute on Drug Abuse or another appropriate federal agency.
Proposed Law:
The bill includes the following provisions, among others:
- Authorizes the program, as hosted by the Center for Medicinal Cannabis Research, to cultivate cannabis for its use in research, as specified.
- Expands the purview of the program’s studies to examine the effect of cannabis on motor skills, the health and safety effects of cannabis, cannabinoids, and other behavioral and health outcomes.
- Authorizes the controlled clinical trials to focus on examining testing methods for detecting harmful contaminants in cannabis, including mold and bacteria.
- Requires funds appropriated to the program to be used only as authorized by the Control, Regulate and Tax Adult Use of Marijuana Act (AUMA).
- Extends, from six months, to every 24 months, the time period the program must submit a report to the Legislature.
Staff Comments:
The bill would require a 2/3-vote of the Legislature.
-- END --
SENATE COMMITTEE ON
BUSINESS, PROFESSIONS AND ECONOMIC DEVELOPMENT
Senator Steven Glazer, Chair
2019 - 2020 Regular
Bill No: AB 420 Hearing Date: June 3, 2019
Author: | Lackey | ||
Version: | May 28, 2019 | ||
Urgency: | Yes | Fiscal: | Yes |
Consultant: | Samantha Tucci | ||
Subject: The California Cannabis Research Program
SUMMARY:
Clarifies that the California Cannabis Research Program (CCRP) is hosted by the Center for Medicinal Cannabis Research (CMCR) and expands the scope of CMCR’s studies to include research on the health effects of natural and synthetic cannabinoids. It also authorizes CMCR to cultivate its own cannabis for research.
Existing law:
- Establishes the Medicinal and Adult-Use Cannabis Regulation and Safety Act (MAUCRSA) to regulate the cultivation, distribution, transport, storage, manufacturing, processing, and sale of both medicinal cannabis and adult-use cannabis. (Business and Professions Code (BPC) § 26000 et seq.)
- Requires the Bureau of Cannabis Control (BCC) to contract with CMCR to develop a study that identifies cannabis’s impact on motor skills. (BPC § 26190.5)
- Requires all commercial cannabis activity to be conducted between cannabis licensees, except as specified. (BPC § 26053 (a))
- States the intent of the Legislature for the state to commission objective scientific research by the University of California (UC) regarding the efficacy and safety of medical cannabis. Requires the UC, by appropriate resolution, to create the California Cannabis Research Program (CCRP). (Health and Safety Code (HSC) § 11362.9(a)(1))
- Requires CCRP to develop and conduct studies to ascertain the general medical safety and efficacy of cannabis and, if valuable, develop medical guidelines for cannabis’s appropriate administration and use. Authorizes these studies to ascertain cannabis’s effects on motor skills. (HSC § 11362.9(a)(2))
- Requires CCRP to be located at one or more UC campuses that have a multidisciplinary faculty core with strong experience in clinical trials involving psychopharmacologic agents. Requires these campuses to accommodate the administrative offices including the CCRP director, a data management unit, and facilities for specimen storage. (HSC § 11362(e)(1))
- Establishes the right of seriously ill Californians to obtain and use cannabis for medical purposes when appropriate and recommended by a physician for the treatment of cancer, anorexia, AIDS, chronic pain, spasticity, glaucoma, arthritis, migraine, or any other illnesses for which cannabis may provide relief. (HSC § 11362.5 (The Compassionate Use Act of 1996))
- Requires CCRP to ensure that all cannabis used in their studies is of appropriate quality and is obtained from the National Institute on Drug Abuse or another appropriate federal agency. If federal agencies fail to provide cannabis within six month, the Attorney General is requires to supply cannabis, as specified. (HSC § 11362.9(j))
- Requires CCRP to conduct focused controlled clinical trials on the usefulness of cannabis in AIDS or HIV, cancer, glaucoma, or seizures or muscle spasms associated with chronic, debilitating conditions. Requires these studies to focus on the efficacy and safety of administration methods and to develop information on dosage, timing, mode of administration, and variations in the effects of different cannabinoids and cannabis varieties. (HSC § 11362.9(l)(1))
- Authorizes CCRP to seek outside funding and prohibits CCRP from accepting funds that are not intended for use other than to solely study the efficacy and safety of cannabis as part of medical treatment. (HSC § 11362.9(n))
- Requires the President of the UC, if the UC Regents implement this code section, to appoint a Scientific Advisory Council to provide policy guidance in the creation and implementation of the CCRP. (HSC § 11362.9(p))
- Requires the Controller to disburse $10,000,000 to a public university or universities in California annually from fiscal year 2018-10 to 2028-29 to research and evaluate the implementation and effect of the Control, Regulate and Tax Adult Use of Marijuana Act. (Revenue and Taxation Code (RTC) § 34019(b))
- Establishes a Research Advisory Panel (Panel) consisting of a representative of the State Department of Health Services; a representative of the California State Board of Pharmacy; the State Public Health Officer; a representative of the Attorney General; a representative of the UC who shall be a pharmacologist, a physician, or a person holding a doctorate degree in the health sciences; a representative of a private university in this state who shall be a pharmacologist, a physician, or a person holding a doctorate degree in the health sciences; a representative of a statewide professional medical society in this state who shall be engaged in the private practice of medicine and shall be experienced in treating controlled substance dependency; a representative appointed by and serving at the pleasure of the Governor who shall have experience in drug abuse, cancer, or controlled substance research and who is either a registered nurse or other health professional. (HSC § 11480 (b))
- Authorizes the Panel to approve and withdraw approval of research projects registered by the Attorney General into the nature and effects of cannabis or hallucinogenic drugs. (HSC § 11480 (g))
This bill:
- Expands Legislative intent to include a directive that the state commission scientific research regarding the efficacy and safety of administering cannabis’s naturally occurring constituents and synthetic compounds as part of medical treatment.
- Specifies that CCRP is hosted by the CMCR.
- Expands the scope of the program’s studies to include the examination of the health and safety effects of cannabis, cannabinoids and other related constituents, and other behavioral health outcomes.
- Requires the UC campuses hosting CCRP to accommodate facilities for the detection and analysis of various naturally occurring and synthetic cannabinoids.
- Authorizes CCRP to cultivate the cannabis used in studies.
- Requires CCRP studies to expand the focus of their studies to include the efficacy, safety, and dosage and administration of synthetic cannabinoid compounds.
- Authorizes CCRP studies to focus on examining testing methods for detecting harmful contaminants in cannabis.
- Authorizes CCRP to accept funds from sources other than government agencies for the study of, or to support the study of, the efficacy, mode of action, and safety of cannabis or natural or synthetic cannabinoids as part of medical treatment, and for the dissemination of information to inform health professionals and the public.
- Lengthens the frequency at which CCRP must issue a report detailing the progress of the studies to the Legislature to every 24 months.
- Requires the director of CMCR, instead of the UC President, to appoint a Scientific Advisory Council.
- Requires that money appropriated to CCRP through RTC § 34019 only be used in compliance with the provisions of AUMA.
- Makes various non-substantive, technical changes.
FISCAL EFFECT:
The Assembly Committee on Appropriations analysis dated April 3, 2019 indicates that this bill has a negligible fiscal effect. Proposition 64, the Control, Regulate, and Tax Adult Use of Marijuana Act, allocates $2 million out of the proceeds of newly created taxes on the sale and cultivation of cannabis to the existing UC cannabis research program referenced in this bill, which is housed at UC San Diego. This bill prohibits an existing $2 million allocation from being used for any new activities requested under this bill. However, Proposition 64 also appropriates an additional $10 million annually from tax proceeds in fiscal years 2018-19 through 2028-29 to fund cannabis-related research. Presumably, some portion of these Proposition 64 funds could be made available to the existing program for the bill's purposes if the research is a state priority and if it fits in one of the funding categories included in the initiative.
COMMENTS:
- Purpose. This bill is sponsored by CMCR. According to the Author, “[the] fact is we still don’t know everything there is to know about cannabis use. The problem, however, is not what we don’t know about it, the problem is that we don’t have enough of the plant to study. CMCR is a premier organization that the Legislature created and trusts; this bill would show how much we trust them and legitimize the research even more.” This bill authorizes CMCR to cultivate cannabis for research.
- Cannabis Regulatory Background. California initially legalized cannabis for medical consumption via Proposition 215, also known as the Compassionate Use Act, in 1996. Proposition 215 protected qualified patients and primary caregivers from prosecution related to the possession and cultivation of cannabis for medicinal purposes. In 2015, the Legislature passed the Medical Cannabis Regulation and Safety Act (MCRSA). MCRSA established for the first time, a comprehensive statewide licensing and regulatory framework for the cultivation, manufacture, transportation, testing, distribution, and sale of medicinal cannabis to be administered by the BCC, the Department of Public Health, and the California Department of Food and Agriculture (CDFA). Shortly following the passage of MCRSA in November 2016, California voters passed Proposition 64, the "Control, Regulate and Tax Adult Use of Marijuana Act" (Proposition 64), which legalized adult-use cannabis. Less than a year later in June 2017, the California State Legislature passed a budget trailer bill, SB 94 (Committee on Budget and Fiscal Review, Chapter 27, Statutes of 2017), that integrated MCRSA with Proposition 64 to create MAUCRSA, the current regulatory structure for both medicinal and adult-use cannabis.
- Cannabis and Cannabinoids in Medicine and Public Safety. In 2017, the National Academies of Science, Engineering, and Medicine (NASEM) released a comprehensive report dedicated to the current understanding of the demonstrated health effects of cannabis and cannabinoids, including cannabidiol (CBD) and the psychoactive molecule, tetrahydrocannabinol (THC).
The report found conclusive evidence of modest therapeutic efficacy for cannabis, cannabis-based products, or synthetic cannabinoids for three conditions: cancer patients experiencing chemotherapy-induced nausea and vomiting, chronic pain, and multiple sclerosis-related spasticity. For other conditions evaluated, NASEM either found no therapeutic effects or inconclusive evidence of effects. Although there is only conclusive evidence for these three conditions, California’s Compassionate Use Act of 1996 established the right for patients to obtain and use cannabis when prescribed for “cancer, anorexia, AIDS, chronic pain, spasticity, glaucoma, arthritis, migraine, or any other illness for which [cannabis] may provide relief.” At this point in time, there is limited information doctors can rely upon to properly discuss, recommend, and prescribe cannabis to patients.
In terms of adverse effects of cannabis, NASEM found substantial, but not conclusive, evidence for:
- Worsening respiratory symptoms and more frequent chronic bronchitis episode associated with long-term cannabis smoking.
- Increased the risk of motor vehicle accidents associate with cannabis use.
- Unintentional cannabis overdose injuries in children.
- Lower birthweight of children with maternal cannabis smoking.
- Development of psychoses associated with frequent cannabis use.
Three cannabis-based medicines have been FDA-approved and are Schedule II drugs.
There are numerous research questions left to be answered relating to both the benefits and risks of cannabis or cannabinoid use both medicinally and recreationally, and how cannabis use will impact public health and safety.
- The Center for Medicinal Cannabis Research. CMCR was created through SB 847 (Vasconcellos, Chapter 750, Statutes of 1999), also known as the Marijuana Research Act of 1999. SB 847 authorized the UC Regents to create a program called the CCRP, which would conduct scientific studies to assess the safety and efficacy of cannabis and, if found valuable, to develop medical guidelines for its appropriate use.
CMCR’s studies have thus far examined the efficacy of cannabis as a painkiller and its value for the treatment of spasticity in multiple sclerosis. Current studies are examining the effects of cannabis on pain, as well as public safety issues surrounding the use of cannabis and CBD.
CMCR is housed at UC San Diego. This bill clarifies that CCRP is hosted by the CMCR, updates its research scope and reporting mandates, and authorizes it to cultivate cannabis.
- Cannabis Access at Research Institutions. There are numerous challenges and barriers to conducting research on cannabis and cannabinoids, including:
- Regulatory barriers, including classification of cannabis as a Schedule I substance.
- Difficulty in obtaining the quantity, quality, and type of cannabis necessary to address relevant research questions.
- Limited funding diversity.
Researchers may currently only obtain cannabis through the National Institute on Drug Abuse’s (NIDA) Drug Supply Program. The University of Mississippi is the only entity authorized by the Drug Enforcement Agency (DEA) to cultivate cannabis for research purposes in the US, and has been since 1968. This has led to supply shortages and created a lack of diversity in cannabis strains and products available for research.
In July 2016, NIDA posted a formal request for information on the varieties of cannabis and cannabis products of interest to researchers. A summary of the comments received stated that: “the most consistent recommendation was to provide marijuana strains and products that reflect the diversity of products available in state dispensaries.” In August of 2016, the DEA announced a policy change to expand the number of registered cannabis manufacturers to provide researchers with a more varied and robust supply of cannabis. According to the DEA’s statement in the Federal Register, the new policy authorizes individuals to register with DEA to grow cannabis not only to supply federally funded or other academic researchers, but also for strictly commercial endeavors funded by the private sector and aimed at drug product development. According to the Brookings Institution, there were 26 applications pending for registration with the DEA as of October 27, 2017. However, the Department of Justice appears to have put these applications on hold.
This bill would authorize CMCR to cultivate cannabis for its own research purposes. They would still need to seek the approval of the DEA to do so within a federally legal framework, however. CMCR would not qualify for a license under the state’s commercial cannabis framework.
- Arguments in Support. According to Eaze, “AB 420 seeks to address potential confusion in cannabis studies and allow for a more comprehensive research option…. By adding synthetic cannabinoids to the readily available substances to study, the scope of research is broadened to include a range of cannabinoids and other cannabis-related compounds that will allow for a more comprehensive study and understanding of the substance. By authorizing CMCR to cultivate their own crop of cannabis (or in collaboration with other Federally-approved entities), researchers will be able to better research the types of cannabis products that may be most beneficial for various conditions, and may be most informative about the potential public health impacts of cannabis use.”
- Current Related Legislation. AB 404 (Stone) would allow a cannabis testing laboratory to amend a certificate of analysis to fix minor errors and to retest a sample if the test result falls outside the specifications authorized by law, the BCC authorizes the test, and the test was compromised due to equipment malfunction, staff error, or other circumstances allowed by the BCC. (Status: This measure is currently pending in the Senate Committee on Business, Professions and Economic Development.)
- Prior Related Legislation. AB 1996 (Lackey) of 2018 would have renamed the “California Marijuana Research Program” (also known as the Center for Medicinal Cannabis Research) to the “California Cannabis Research Program” in areas of the code where this change has not yet been made. It would have expanded the potential research areas of CCRP to include the study of synthetic compounds that have similar effects to cannabis and to examine the health and safety effects of cannabis and other issues. It would have authorized CCRP to cultivate cannabis, in compliance with federal regulations. (Status: This measure was vetoed by Governor Brown for conflicting with the Control, Regulate, and Tax Adult Use of Marijuana Act.)
AB 1002 (Cooley) of 2017 would have changes the name of the “California Marijuana Research Program” to the “Center for Cannabis Research,” expanded its research and reporting mandates, and authorized the CCRP to cultivate cannabis to be used exclusively for research purposes and contract with a private entity to provide expertise in cultivating medical cannabis. (Status: This measure was held in the Senate Committee on Appropriations.)
SB 94 (Committee on Budget and Fiscal Review, Chapter 27, Statutes of 2017) was the cannabis trailer bill for the Budget Act of 2017. Among other items, it required the BCC to contract with CCRP to develop a study that identifies the impact of cannabis on motor skills.
AB 2679 (Cooley, Chapter 828, Statutes of 2016) authorized CCRP to develop and conduct studies to ascertain the effect of cannabis on motor skills and required cannabis licensing authorities to issue annual reports, as specified.
SB 643 (McGuire, Chapter 719, Statutes of 2015) stated legislative intent to commission objective scientific research by the UC on the efficacy and safety of administering cannabis as part of medical treatment. Required the UC, if it accepted by resolution, to create the CMRP to develop and conduct studies on the general medical safety and efficacy of cannabis, and if found valuable, to develop medical guidelines for the appropriate administration and use of cannabis.
AB 243 (Wood, Chapter 688, Statutes of 2015) established a regulatory program for the cultivation of medical cannabis as part of the Medical Marijuana Regulation and Safety Act.
AB 266 (Bonta, Chapter 689, Statutes of 2015) required the BCC to contract with the CMRP to develop a study that identifies the impact of medical cannabis on motor skills.
SB 847 (Vasconcellos, Chapter 750, Statutes of 1999) permitted the UC to implement a three-year program, the CMRP, to study the safety and efficacy of cannabis for medical purposes.
- Suggested Amendments. This bill proposes to allow CMCR to cultivate cannabis, but upon further discussions it is clear that CMCR would also like to work with licensed cannabis businesses to manufacture or otherwise obtain cannabis products for research purposes. CMCR currently must seek approval from the Panel to conduct research projects concerning the nature and effects of cannabis.
The Committee may wish to consider the following amendments to provide additional oversight for CMCR’s cannabis cultivation and expand opportunities for CMCR to collaborate with licensed cannabis businesses. The amendments below propose to allow the Panel to authorize CMCR to cultivate or otherwise obtain cannabis products directly from licensed cannabis businesses for research purposes, providing an additional level of oversight in exchange for expanded authority.
On page 6, line 22, after “program,” insert “,pursuant to Section 11480.”
On page 9, between lines 3 and 4, insert: “Section 11480 of the Health and Safety Code line 2 is amended to read:
(i) The panel may authorize an institution conducting a research project registered by the Attorney General to cultivate cannabis for the research project. Notwithstanding any other law, the panel may also authorize the institution to work with individuals licensed pursuant to the Medicinal and Adult-Use Cannabis regulation and Safety Act for the purpose of cultivating, testing, manufacturing, or procuring cannabis products for research projects.”
SUPPORT AND OPPOSITION:
Support:
California Cannabis Coalition
Cal NORML
Eaze
NorCal Cannabis
Opposition:
None on file as of May 29, 2019.
-- END --
Date of Hearing: April 3, 2019
ASSEMBLY COMMITTEE ON APPROPRIATIONS
Lorena Gonzalez, Chair
ABPCA Bill Id:AB 420
Author:(Lackey) – As Introduced Ver:February 7, 2019
Policy Committee: | Business and Professions | Vote: | 20 - 0 |
Urgency: Yes State Mandated Local Program: No Reimbursable: No
SUMMARY:
This bill broadens the charge of an existing state cannabis research program at the University of California (UC) by authorizing the study of synthetic cannabanoids, among other topics, and authorizes the program to cultivate cannabis for research purposes.
FISCAL EFFECT:
Negligible. Proposition 64, the Control, Regulate, and Tax Adult Use of Marijuana Act, allocates $2 million out of the proceeds of newly created taxes on the sale and cultivation of cannabis to the existing UC cannabis research program referenced in this bill, which is housed at UC San Diego. This bill prohibits an existing $2 million allocation from being used for any new activities requested under this bill. However, Proposition 64 also appropriates an additional $10 million annually from tax proceeds in fiscal years 2018-19 through 2028-29 to fund cannabis-related research. Presumably, some portion of these Proposition 64 funds could be made available to the existing program for the bill's purposes if the research is a state priority and if it fits in one of the funding categories included in the initiative.
COMMENTS:
- Purpose. The author indicates this bill updates statute to reflect current work, adds additional topics of interest and allows the cultivation for research purposes. It is sponsored by the Center for Medical Cannabis Research at UC San Diego and has no opposition.
- Background. In 1996, California voters passed Proposition 215, legalizing the use of medical cannabis in the state. SB 847 (Vasconcellos), Chapter 750, Statutes of 1999, established the UC Center for Medical Cannabis Research, now the California Cannabis Research Program at UC San Diego. This bill specifies the research program is hosted by the Center for Medical Cannabis Research. The state began regulating medical cannabis in 2016 and later that year California voters passed Proposition 64, which legalized the recreational use of cannabis beginning in 2018.
- Prior Legislation. AB 1996 (Lackey), of the 2017-18 Legislative Session, was similar to this bill and was vetoed based on concerns it contained provisions that directly conflict with Proposition 64. It is unclear whether this bill addresses concerns raised in the veto message.
AB 1002 (Cooley) was substantially similar to this bill and was held on the Suspense File of the Senate Appropriations Committee.
Analysis Prepared by: Lisa Murawski / APPR. / (916) 319-2081
Date of Hearing: March 26, 2019
ASSEMBLY COMMITTEE ON BUSINESS AND PROFESSIONS
Evan Low, Chair
ABPCA Bill Id:AB 420
Author:(Lackey) – As Introduced Ver:February 7, 2019
SUBJECT: The California Cannabis Research Program.
SUMMARY: Classifies the existing program at the University of California, San Diego (UCSD) as “The Center for Medicinal Cannabis Research”, allows The Center for Medicinal Cannabis Research (CMCR), on the campus of UCSD, to produce their own cannabis. Also, creates necessary expansions to the law to allow the center to study more fully the health effects of cannabis including pure, and synthetic cannabinoids.
EXISTING LAW:
- Establishes the Bureau of Cannabis Control (Bureau) under the Department of Consumer Affairs, to establish a comprehensive system to control and regulate the distribution, transport, storage, and sale of cannabis products. (Business and Professions Code Section 26000 et seq.)
- Authorizes the Medical Board of California to consult with the California Marijuana Research Program, known as the CMCR, on developing and adopting medical guidelines for the appropriate administration and use of medical cannabis. (Business and Professions Code Section 2525.1)
- Directs the Bureau to contract with the California Cannabis Research Program, known as the CMCR, to develop a study that identifies the impact that cannabis has on motor skills. (Business and Professions Code Section 19354)
- States the intent of the Legislature that the state commission’s objective is scientific research by the University of California, regarding the efficacy and safety of administering cannabis as part of medical treatment. (Health and Safety Code Section 11362.9 (a)(1))
- Authorizes the Regents of the University of California, by appropriate resolution, to direct the University of California to create a program, to be known as the California Cannabis Research Program. (Health and Safety Code Section 11362.9 (a)(1))
- Specifies that the California Cannabis Research Program shall develop and conduct studies intended to ascertain the general medical safety and efficacy of cannabis and develop medical guidelines for the appropriate administration and use of cannabis including the effect of cannabis on motor skills. (Health and Safety Code Section 11362.9 (a)(2))
- Requires the California Cannabis Research Program to ensure that all cannabis used in the studies is of appropriate quality and shall be obtained from the National Institute on Drug Abuse or the Attorney General, pursuant to Health and Safety Code Section 11478. (Health and Safety Code Section 11362.9(j))
- Establishes specific continuous appropriation of state tax revenue relating to commercial cannabis activity, including an annual appropriation of $10 million to a public university or
universities, from 2018-19 to 2028-29, for research and evaluation of the legal cannabis market. (Revenue and Taxation Code Section 34019(b))
THIS BILL:
- Will clarify that research is hosted by the “Center for Medicinal Cannabis Research.” (CMCR)
- Allows CMCR researchers to expand their scope of study to effectively perform research on the health effects of cannabis and pure, including synthetic, cannabinoids.
- Will allow CMCR to cultivate its own cannabis for research.
FISCAL EFFECT: Unknown; this bill is keyed fiscal by the Legislative Counsel.
COMMENTS:
Purpose. This bill is sponsored by CMCR. According to the Author, “The fact is we still don’t know everything there is to know about cannabis use. The problem, however, is not what we don’t know about it, the problem is that we don’t have enough of the plant to study. CMCR is a premier organization that the Legislature created and trusts; this bill would show how much we trust them and legitimize the research even more.”
Background. Cannabis. The cannabis plant produces a resin containing compounds called cannabinoids, which are the active ingredients that directly affect the central nervous and immune systems in the human body. Some cannabinoids are psychoactive, which act on the brain and have the potential to alter mood or consciousness. Two of the primary active cannabinoids within the cannabis plant are tetrahydrocannabinol (THC) and cannabidiol (CBD). Results from the limited research on the medicinal properties and adverse effects of cannabis suggest that cannabinoids are associated with improved symptoms of patients with a variety of clinical symptoms, though not all studies have yielded statistically significant results. For example, some studies provide limited evidence that cannabinoids may be beneficial for conditions such as spasticity resulting from multiple sclerosis, and pain due to chronic neuropathy and cancer. However, clinical trials on the medical efficacy of cannabis are extremely limited because the federal government considers the cannabis plant a Schedule I drug, and therefore it is considered a dangerous controlled substance with no accepted medical benefits and a high potential for abuse.
History of Legal Cannabis in California. In 1996, California voters passed Proposition 215, legalizing the use of medical cannabis in the state. In October 2015, nearly 20 years after the authorization of the use of MC, Governor Jerry Brown signed into law a trio of bills [AB 243 (Wood), Chapter 688, Statutes of 2015, AB 266 (Bonta, Cooley, Jones-Sawyer, Lackey, and Wood), Chapter 689, Statutes of 2015, and SB 643 (McGuire), Chapter 719, Statutes of 2015] collectively known as the Medical Cannabis Regulation and Safety Act (MCRSA). MCRSA established the state's first regulatory framework for medical cannabis. In 2016, the voters of California passed Proposition 64, the Adult Use of Marijuana Act (AUMA), to legalize the recreational use of cannabis in the state by 2018. In June 2017, MCRSA AUMA were combined via the budget process to form one system for the regulation of Cannabis, the Medicinal and Adult-Use Cannabis Regulation and Safety Act (MAUCRSA).
Cannabis Research in California. Currently, the entity engaging in research at the University of California, San Diego, is listed under various names, which may cause confusion when discussing cannabis studies. Existing Law requires the University of California to establish the California Cannabis Research Program, which was ultimately named the CMCR (also referred to as such in AB 266). However this has not been specifically confirmed in current law.
In 2000, the CMCR at University of California, San Diego was created through Senate Bill 847 (1999) to conduct scientific studies to assess the safety and efficacy of cannabis compounds for treating medical conditions. The Program has since made important findings regarding the effects of cannabis in clinical trials, demonstrating reductions in neuropathic pain, as well as spasticity associated with multiple sclerosis.
The CMCR serves as a hub for cannabis research throughout the State of California. Research has focused on the potential medicinal benefits of cannabis for diseases and conditions identified by the National Academy of Sciences, Institute of Medicine Report (1999) and by the Workshop on the Medical Utility of Marijuana, National Institutes of Health (1997). Studies have examined the analgesic efficacy of cannabis on experimental models of neuropathic pain, neuropathic pain from HIV and diabetes, and neuropathic pain of diverse etiology. Additionally, studies have evaluated the efficacy of cannabis for the treatment of spasticity in multiple sclerosis. Additionally, the Center will be assisting the state of California in evaluating the effects of cannabis on driving pursuant to AB 266 (Bonta), Chapter 689, Statutes of 2015, and consulting with the California Medical board on prescribing practices pursuant to SB 643 (McGuire), Chapter 719, Statutes of 2015.
The University of California is established in the California Constitution as an independent entity. Therefore, the Legislature has very limited control over the University. Therefore, existing law relating to the Center for Cannabis Research generally requests the University to establish the program or states legislative intent that the Program to undertake specified activities.
Funding for cannabis research. Proposition 64 (2016), which legalized adult-use cannabis, allocates a portion of the state tax collections from cannabis activity for specified purposes. Included in those allocations is $2 million per year for the University of California San Diego CMCR (host of the California Cannabis Research Program). This bill prohibits that funding to be used for any new activities requested under this bill. However, those funds can be used to support the Program and fund other cannabis-related research. In addition, Proposition 64 allocates $10 million per year for research at public universities, some portion of which may be made available to the Program. For example, in the past the Program was the administering agency for some state funding made available for cannabis research.
Cannabis Research at the University of Mississippi. The University of Mississippi is the sole entity authorized by the Drug Enforcement Agency (DEA) to produce cannabis for research in the United States. This has led to shortages in supply and a lack of diversity in products available for medicinal research. Although the DEA has permitted applicants to be registered under the controlled substances act to cultivate cannabis for supply to researchers, no action has been taken on the applications and the University of Mississippi remains the sole provider.
Expansion, in order to better understand the mechanisms by which cannabis might exert beneficial, or negative effects, can be helpful to study the effects of pure cannabinoids and associated compounds (e.g., terpenes). This research option is not explicitly stated in existing law relating to the CMCR.
2016 DEA Policy on Cannabis Supplied for Research Purposes. On August 11, 2016, the DEA announced a policy change designed to foster research by expanding the number of DEA- registered cannabis manufacturers. This change is intended to provide researchers with a more varied and robust supply of cannabis. The DEA’s new policy will allow additional entities to apply to become registered with the DEA so that they may grow and distribute cannabis for FDA-authorized research purposes. However, the Department of Justice appears to have put all applications for registration on hold.
Prior Related Legislation.
AB 710 (Wood) of 2018 amends the Medicinal and Adult-Use Cannabis Regulation and Safety Act to exclude federally sanctioned CBD products from regulation and authorizes healing arts licensees to prescribe such products, as specified. Chaptered.
AB 1996 (Lackey) of 2018 – Vetoed by Governor for conflicts with AUMA
AB 1002 (Cooley) of 2017 was similar to AB 1996 of 2018, and would also have expanded the research and reporting authorities of the Program. Bill was held in the Senate Appropriations Committee.
SB 94 (Committee on Budget and Fiscal Review, Chapter 27, Statutes of 2017) was the cannabis trailer bill for the Budget Act of 2017. Among other items, it required the Bureau to contract with the Program to develop a study that identifies the impact of cannabis on motor skills.
AB 2679 (Cooley, Bonta, Jones-Sawyer, Lackey, Wood, Chapter 828, Statutes of 2016) required cannabis licensing authorities to include annual reports about the number of appeals for license denials, disciplinary actions, and complaints. Authorizes the University of California’s California Cannabis Research Program to develop and conduct studies to ascertain the effect of cannabis on motor skills.
SB 643 (McGuire) Chapter 719, Statutes of 2015 stated legislative intent to commission objective scientific research by the UC regarding the efficacy and safety of administering cannabis as part of medical treatment. Requires UC, if it accepts by appropriate resolution the responsibility to create a California Marijuana Research Program (Program) that it will develop and conduct studies intended to ascertain the general medical safety and efficacy of cannabis, and if found valuable, to develop medical guidelines for the appropriate administration and use of cannabis.
AB 266 (Bonta, Cooley, Jones-Sawyer, Lackey, Wood) Chapter 689, Statutes of 2015 requires the Bureau to contract with Program to develop a study that identifies the impact of medical cannabis on motor skills.
SB 295 (Vasconcellos) Chapter 704, Statutes of 2003 eliminated the three-year sunset date on the Program, thereby extending it indefinitely.
SB 847 (Vasconcellos) Chapter 750, Statutes of 1999 established the Center for Medicinal Marijuana Research as the Medical Marijuana Research Program to study the safety and efficacy of cannabis usage for medical purposes.
ARGUMENTS IN SUPPORT:
According to the Author, “The fact is we still don’t know everything there is to know about cannabis use. The problem, however, is not what we don’t know about it, the problem is that we don’t have enough of the plant to study. CMCR is a premier organization that the Legislature created and trusts; this bill would show how much we trust them and legitimize the research even more.”
ARGUMENTS IN OPPOSITION:
None on file.
AMENDMENTS:
Anticipated Amendments. The bill appropriates funds by authorizing money from the California Cannabis Tax Fund to be used for a new purpose.
Removes section (s) and includes new language that states that this bill would not fund the additional activities outlined in the bill from the $2,000,000 allocated yearly by the controller (Rev and Tax: subd. E Section 34019).
REGISTERED SUPPORT:
Center for Medicinal Cannabis Research (Sponsor)
NorCal Cannabis Company
REGISTERED OPPOSITION:
None on file.
Analysis Prepared by: Danielle Sires / B. & P. / (916) 319-3301
Bill Author
Bill Co-Author(s):